Protecting the kidneys during and after cardiac surgery remains one of the most stubborn unsolved problems in perioperative medicine — acute kidney injury following heart surgery affects roughly 20-30% of patients and meaningfully worsens survival, hospital length of stay, and long-term renal function. The hypothesis that SGLT2 inhibitors might help was scientifically compelling enough to warrant a rigorous randomized trial published in JAMA.
The trial assigned patients undergoing elective cardiac surgery to either a single dose of dapagliflozin administered one day before the procedure or placebo, then tracked AKI incidence across the seven days following surgery. Despite dapagliflozin's well-established renoprotective mechanisms in chronic kidney disease and heart failure populations — including reduced glomerular hyperfiltration, anti-inflammatory effects, and tubular metabolic optimization — the pre-operative dosing strategy did not significantly reduce AKI rates compared with placebo. The null result held across the primary endpoint and appears consistent across the surgical cohort studied.
This finding is scientifically important precisely because the biological rationale was strong. In chronic disease settings, SGLT2 inhibitors reduce renal stress by lowering intraglomerular pressure and shifting tubular energy metabolism toward more efficient substrate utilization. However, cardiac surgery introduces acute ischemia-reperfusion injury, hemodynamic instability, cardiopulmonary bypass, and inflammatory cascades that likely overwhelm mechanisms operative in stable chronic conditions. A single pre-operative dose may be pharmacologically insufficient to prime renal cytoprotection against such an abrupt and severe insult. This trial reinforces a broader pattern in perioperative research: interventions with strong chronic disease efficacy frequently fail to translate to acute surgical contexts. The result is best characterized as genuinely informative rather than disappointing — it narrows the translational gap and redirects attention toward intraoperative or multi-dose perioperative SGLT2 inhibitor protocols, or fundamentally different renoprotective strategies for surgical patients.